236 related articles for article (PubMed ID: 32634775)
1. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer.
Le X; Ferrarotto R; Wise-Draper T; Gillison M
J Natl Compr Canc Netw; 2020 Jul; 18(7):899-906. PubMed ID: 32634775
[TBL] [Abstract][Full Text] [Related]
2. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
5. Managing Recurrent Metastatic Head and Neck Cancer.
Shaikh H; Karivedu V; Wise-Draper TM
Hematol Oncol Clin North Am; 2021 Oct; 35(5):1009-1020. PubMed ID: 34226077
[TBL] [Abstract][Full Text] [Related]
6. Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.
van der Linden N; Buter J; Pescott CP; Lalisang RI; de Boer JP; de Graeff A; van Herpen CM; Baatenburg de Jong RJ; Uyl-de Groot CA
Eur Arch Otorhinolaryngol; 2016 Feb; 273(2):455-64. PubMed ID: 25876000
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy for head and neck squamous cell carcinoma].
Lecocq M; Poncin A; Sautois B
Rev Med Liege; 2021 May; 76(5-6):398-402. PubMed ID: 34080370
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
[TBL] [Abstract][Full Text] [Related]
9. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinoma of head and neck: what internists should know.
Jung K; Narwal M; Min SY; Keam B; Kang H
Korean J Intern Med; 2020 Sep; 35(5):1031-1044. PubMed ID: 32663913
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for squamous cell carcinoma of the head and neck.
Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
[TBL] [Abstract][Full Text] [Related]
12. ["Immunotherapy in head and neck squamous cell carcinoma"].
Marret G; Borcoman É; Le Tourneau C
Rev Prat; 2021 Apr; 71(4):396-399. PubMed ID: 34161005
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
14. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
16. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Mody MD; Gill HS; Saba NF
JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
18. [Ⅰ. Photo-Immunotherapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck].
Sano D; Oridate N
Gan To Kagaku Ryoho; 2023 Jul; 50(7):775-780. PubMed ID: 37496220
[No Abstract] [Full Text] [Related]
19. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
Rancoule C; Vallard A; Espenel S; Guy JB; Xia Y; El Meddeb Hamrouni A; Rodriguez-Lafrasse C; Chargari C; Deutsch E; Magné N
Oral Oncol; 2016 Nov; 62():153-162. PubMed ID: 27623508
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]